Blood Reviews最新文献

Classic Hodgkin lymphoma: Pathobiological features that impact emerging therapies. 经典霍奇金淋巴瘤：影响新兴疗法的病理生物学特征。

IF 6.9 2区医学

Blood Reviews Pub Date : 2025-01-30 DOI: 10.1016/j.blre.2025.101271

Mohamed Nazem Alibrahim, Annunziata Gloghini, Antonino Carbone

{"title":"Classic Hodgkin lymphoma: Pathobiological features that impact emerging therapies.","authors":"Mohamed Nazem Alibrahim, Annunziata Gloghini, Antonino Carbone","doi":"10.1016/j.blre.2025.101271","DOIUrl":"https://doi.org/10.1016/j.blre.2025.101271","url":null,"abstract":"<p><p>Classic Hodgkin lymphoma (cHL) is defined by distinctive Hodgkin Reed-Sternberg (HRS) cells, which are CD30+/CD15+ multinucleated tumor cells lacking typical B-cell markers. These cells comprise <5 % of tumor mass but orchestrate an extensive immunosuppressive tumor microenvironment (TME). Classic HL was curable with radiation therapy and multi-agent chemotherapy. Despite high cure rates, treatment-related toxicities remain significant. The goals of multimodality therapy are to achieve a cure while minimizing treatment-associated toxicity. Advances in molecular insights into HRS cells have led to transformative therapies, including checkpoint inhibitors, antibody-drug conjugates like brentuximab vedotin, which have shown remarkable efficacy, especially in relapsed or refractory disease. However, challenges persist due to the heterogeneity of cHL, driven by the complex biology of HRS cells and their surrounding tumor microenvironment. Novel approaches such as single-cell RNA sequencing and circulating tumor DNA profiling provide promising strategies to address these challenges. This review examines the origin, morphology, phenotype, and genetic profiles of HRS cells, highlighting key pathobiological features, including biomarkers and Epstein-Barr Virus involvement. It also explores the biological mechanisms underlying HRS cell survival and evaluates standard and emerging therapies, offering insights into the rationale for novel treatment strategies.</p>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":" ","pages":"101271"},"PeriodicalIF":6.9,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143191489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PET scan for the detection of histological transformation of follicular lymphoma: A systematic review of diagnostic performance.

IF 6.9 2区医学

Blood Reviews Pub Date : 2025-01-28 DOI: 10.1016/j.blre.2025.101270

Marc Sorigue, Milos Miljkovic, Pablo Mozas

{"title":"PET scan for the detection of histological transformation of follicular lymphoma: A systematic review of diagnostic performance.","authors":"Marc Sorigue, Milos Miljkovic, Pablo Mozas","doi":"10.1016/j.blre.2025.101270","DOIUrl":"https://doi.org/10.1016/j.blre.2025.101270","url":null,"abstract":"<p><p>The strength of evidence supporting use of PET in the evaluation of suspected histological transformation (HT) of follicular lymphoma (FL) is unknown. We conducted a systematic review of studies reporting the diagnostic performance of ≥1 PET parameters for the detection of HT in patients with known FL. We searched PubMed for any study reporting ≥1 diagnostic performance metrics. Risk of bias was evaluated with the QUADAS2 tool. We included 7 studies encompassing 152 patients with a biopsy showing FL (or indolent non-Hodgkin lymphoma) and 111 with a biopsy confirming HT. Study designs and study populations differed substantially. PET methods were poorly reported and <sup>18</sup>F-FDG dose was highly variable. Most studies were judged to be at high risk of bias in the patient and index test domains of QUADAS2. The diagnostic performance of 5 PET parameters were reported in at least one study but only SUVmax (n = 7) was reported in >2. Median SUVmax ranged from 9.2 to 10.9 in FL/iNHL and from 13.7 to 24.4 in HT. While SUVmax was consistently higher in the HT group, there was considerable overlap between the two groups and significant variability between studies. Area under the ROC curve for SUVmax to distinguish between FL/iNHL and HT ranged from 0.68 to 0.97. Sensitivity and specificity of the proposed cutoffs also varied widely (sensitivity ∼0.6 to 1, specificity ∼0.4 to 1). In conclusion, few studies - mostly small and potentially biased - have addressed this question. Although SUVmax is generally higher in HT than in FL, the diagnostic performance and optimal cutoffs remain unclear. Proposed SUVmax cutoffs should not be used to determine whether a patient has HT or to decide whether a biopsy should be obtained. For now, we encourage physicians to evaluate results of their own practice to devise a prudent workup of suspected.</p>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":" ","pages":"101270"},"PeriodicalIF":6.9,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143076404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

BTKi-induced cardiovascular toxicity in CLL: Risk mitigation and management strategies.

IF 6.9 2区医学

Blood Reviews Pub Date : 2025-01-24 DOI: 10.1016/j.blre.2025.101268

Sofija Kozarac, Vojin Vukovic, Michael Fradley, Darko Antic

{"title":"BTKi-induced cardiovascular toxicity in CLL: Risk mitigation and management strategies.","authors":"Sofija Kozarac, Vojin Vukovic, Michael Fradley, Darko Antic","doi":"10.1016/j.blre.2025.101268","DOIUrl":"https://doi.org/10.1016/j.blre.2025.101268","url":null,"abstract":"<p><p>Targeted therapies, consisting of Bruton tyrosine kinase inhibitors (BTKis) or BCL-2 inhibitors, are the mainstay of contemporary treatments for chronic lymphocytic leukemia (CLL). The most common adverse effects (AEs) of BTKis are fatigue, bruising, infection, hematological and cardiovascular AEs. While AEs during treatment are usually mild (grades 1 and 2), grade 3 and 4 AEs have been detected in some patients, necessitating additional medical care and temporary or permanent drug discontinuation. In this review, we analyzed the cardiovascular effects associated with BTKi therapy for CLL and the essential practical aspects of multidisciplinary management of patients who develop cardiovascular toxicity during treatment. We particularly focus on the data and strategies for controlling cardiovascular risks associated with ibrutinib and newer BTKis (acalabrutinib, zanubrutinib and pirtobrutinib), including the development of atrial fibrillation, hypertension, ventricular arrhythmias, sudden death, heart failure, bleeding, and ischemic complications (stroke and myocardial infarction). This review highlights hematological insights underlying cardiotoxicity, an area that has received limited attention in comparison to the predominantly cardiological perspective. This review synthesizes emerging evidence on hematological biomarkers, cardiotoxic mechanisms, and therapeutic interventions, linking hematology and cardiology to enhance understanding and guide comprehensive prevention and management strategies.</p>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":" ","pages":"101268"},"PeriodicalIF":6.9,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143069746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Radiotherapeutics, clonal hematopoiesis, and risk of hematologic malignancies: The good, the bad, the ugly.

IF 6.9 2区医学

Blood Reviews Pub Date : 2025-01-22 DOI: 10.1016/j.blre.2025.101269

Catherine H Marshall, Emmanuel S Antonarakis, Mrinal M Patnaik

引用次数: 0

Corrigendum to "Impact of transcranial Doppler screening on stroke prevention in children and adolescents with sickle cell disease: A systematic review and meta-analysis" [Blood Reviews (2024) 101253]. “经颅多普勒筛查对镰状细胞病儿童和青少年卒中预防的影响：一项系统综述和荟萃分析”[Blood Reviews(2024) 101253]的更正。

IF 6.9 2区医学

Blood Reviews Pub Date : 2025-01-17 DOI: 10.1016/j.blre.2025.101258

Danielle Guy, Robert Bagnall, Rebecca L Morgan, Ifeoluwa Babatunde, Agathe Nevière, Gabriela Friedrich, Liga Bennetts, Omar Irfan, Isaac Odame

引用次数: 0

Application of thrombopoietic agents in cancer therapy-induced thrombocytopenia: A comprehensive review. 造栓剂在癌症治疗性血小板减少症中的应用综述。

IF 6.9 2区医学

Blood Reviews Pub Date : 2025-01-11 DOI: 10.1016/j.blre.2025.101257

Junyang Mei, Feng Jiao, Yiping Li, Jiujie Cui, Haiyan Yang, Liwei Wang

引用次数: 0

Mechanisms for resistance to BCMA-targeted immunotherapies in multiple myeloma. 多发性骨髓瘤对bcma靶向免疫疗法的耐药机制。

IF 6.9 2区医学

Blood Reviews Pub Date : 2025-01-11 DOI: 10.1016/j.blre.2025.101256

Tingting Yue, Yue Sun, Yun Dai, Fengyan Jin

引用次数: 0

Bispecific antibodies for the treatment of hematologic malignancies: The magic is T-cell redirection 治疗血液系统恶性肿瘤的双特异性抗体：神奇的是t细胞重定向。

IF 6.9 2区医学

Blood Reviews Pub Date : 2025-01-01 DOI: 10.1016/j.blre.2024.101251

Geoffrey Shouse

引用次数: 0

The intestinal flora: The key to unraveling heterogeneity in immune thrombocytopenia? 肠道菌群：揭示免疫性血小板减少症异质性的关键？

IF 6.9 2区医学

Blood Reviews Pub Date : 2025-01-01 DOI: 10.1016/j.blre.2024.101252

Jente M. Schoenaker , Vivianne S. Nelson , Jannie G.E. Henderickx , Elisabeth M. Terveer , A.J. Gerard Jansen , Leendert Porcelijn , Tanja Netelenbos , Martin R. Schipperus , Rick Kapur

{"title":"The intestinal flora: The key to unraveling heterogeneity in immune thrombocytopenia?","authors":"Jente M. Schoenaker , Vivianne S. Nelson , Jannie G.E. Henderickx , Elisabeth M. Terveer , A.J. Gerard Jansen , Leendert Porcelijn , Tanja Netelenbos , Martin R. Schipperus , Rick Kapur","doi":"10.1016/j.blre.2024.101252","DOIUrl":"10.1016/j.blre.2024.101252","url":null,"abstract":"<div><div>Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder characterized by enhanced platelet destruction and impaired platelet production, due to a loss of immune tolerance that leads to targeting of platelets and megakaryocytes by glycoprotein-autoantibodies and/or cytotoxic T cells. There is a high degree of heterogeneity in ITP patients signified by unpredictable disease trajectories and treatment responses. Initial studies in humans have identified intestinal microbiota perturbance in ITP. Recently, gut microbial perturbance has been linked to other autoimmune diseases. Based on these findings, we hypothesize that intestinal microbiota may influence ITP pathophysiology through several mechanisms, including induction of platelet-autoantibody production, increasing complement-dependent platelet cytotoxicity, disturbing T cell homeostasis, impairing megakaryocyte function, and increasing platelet-desialylation and -clearance. The pathophysiological heterogeneity of ITP may, at least in part, be attributed to a perturbed intestinal microbiota. Therefore, a better understanding of intestinal microbiota in ITP may result in a more personalized therapeutic approach.</div></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"69 ","pages":"Article 101252"},"PeriodicalIF":6.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142823012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of transcranial Doppler screening on stroke prevention in children and adolescents with sickle cell disease: A systematic review and meta-analysis 经颅多普勒筛查对儿童和青少年镰状细胞病卒中预防的影响：系统回顾和荟萃分析

IF 6.9 2区医学

Blood Reviews Pub Date : 2025-01-01 DOI: 10.1016/j.blre.2024.101253

Danielle Guy , Robert Bagnall , Rebecca L. Morgan , Ifeoluwa Babatunde , Agathe Nevière , Gabriela Friedrich , Liga Bennetts , Omar Irfan , Isaac Odame

{"title":"Impact of transcranial Doppler screening on stroke prevention in children and adolescents with sickle cell disease: A systematic review and meta-analysis","authors":"Danielle Guy , Robert Bagnall , Rebecca L. Morgan , Ifeoluwa Babatunde , Agathe Nevière , Gabriela Friedrich , Liga Bennetts , Omar Irfan , Isaac Odame","doi":"10.1016/j.blre.2024.101253","DOIUrl":"10.1016/j.blre.2024.101253","url":null,"abstract":"<div><h3>Background</h3><div>Children with sickle cell disease (SCD) have increased stroke risk, identifiable by elevated velocities on transcranial Doppler (TCD). This review assessed the impact of TCD screening on stroke, mortality, quality of life and morbidity in children with SCD.</div></div><div><h3>Methods</h3><div>A systematic search of MEDLINE, PubMed, Cochrane libraries, and trial registries was conducted from inception to 28th February 2023. Randomised controlled trials (RCTs) and non-randomised studies (NRS) were included. A meta-analysis and narrative synthesis were performed.</div></div><div><h3>Findings</h3><div>Nine studies were included in the review. In one RCT, initiating chronic blood transfusion in children with abnormal TCD velocities reduced stroke risk by 92 %, while no deaths were reported. Pooled results from three NRS indicated TCD screening leads to four fewer strokes per 1000 patients annually. No studies analysing morbidity nor quality of life were identified.</div></div><div><h3>Interpretation</h3><div>TCD screening may decrease the risk of stroke in patients with SCD.</div></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"69 ","pages":"Article 101253"},"PeriodicalIF":6.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142878008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0